The role of bone marrow stromal cells in blood diseases and clinical significance as a crucial part of the hematopoietic microenvironment

Liang, Xinyan; Song, Erwei

doi:10.21037/aob.2019.12.03

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bone marrow stromal cells (BMSCs) are integral with BMSC-derived CXC-chemokine ligand 12 promoting the homing of plasma cells to the BM [ 60 ]. Physical interactions between BMSCs and plasma cells activates NF-κB and MAPK1 signalling pathways and promotes secretion of cytokines favouring plasma cell proliferation, inhibition of apoptosis and resistance to therapy [ 61 , 62 ]. BMSCs additionally secrete receptor activator of nuclear factor-κB ligand (RANKL) promoting osteoclast maturation.…”

Section: Advances On the Pathobiology Of Myelomamentioning

confidence: 99%

Shaping the Treatment Paradigm Based on the Current Understanding of the Pathobiology of Multiple Myeloma: An Overview

Ninkovic

Quach

2020

Cancers

View full text Add to dashboard Cite

Multiple myeloma is an incurable malignancy which despite progressive improvements in overall survival over the last decade remains characterised by recurrent relapse with progressively shorter duration of response and treatment-free intervals with each subsequent treatment. Efforts to unravel the complex and heterogeneous genomic alterations, the marked dysregulation of the immune system and the multifarious interplay between malignant plasma cells and those of the tumour microenvironment have not only led to improved understanding of myelomagenesis and disease progression but have facilitated the rapid development of novel therapeutics including immunotherapies and small molecules bringing us a step closer to therapies that no doubt will extend survival. Novel therapeutic combinations both in the upfront and relapsed setting as well as novel methods to assess response and guide management are rapidly transforming the management of myeloma.

show abstract

Section: Advances On the Pathobiology Of Myelomamentioning

confidence: 99%

Shaping the Treatment Paradigm Based on the Current Understanding of the Pathobiology of Multiple Myeloma: An Overview

Ninkovic

Quach

2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Together they form the skeletal structure of the BM and generate a permissive environment that influences the function and differentiation of hematopoietic cells. In MM, BMSCs strongly interact with malignant PCs in a reciprocally supporting manner towards cancer progression ( 19 ).…”

Section: The Tumor Microenvironment In Multiple Myelomamentioning

confidence: 99%

Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors

Schwestermann

Bešše

2022

Front. Oncol.

View full text Add to dashboard Cite

Virtually all patients with multiple myeloma become unresponsive to treatment with proteasome inhibitors over time. Relapsed/refractory multiple myeloma is accompanied by the clonal evolution of myeloma cells with heterogeneous genomic aberrations, diverse proteomic and metabolic alterations, and profound changes of the bone marrow microenvironment. However, the molecular mechanisms that drive resistance to proteasome inhibitors within the context of the bone marrow microenvironment remain elusive. In this review article, we summarize the latest knowledge about the complex interaction of malignant plasma cells with its surrounding microenvironment. We discuss the pivotal role of metabolic reprograming of malignant plasma cells within the tumor microenvironment with a subsequent focus on metabolic rewiring in plasma cells upon treatment with proteasome inhibitors, driving multiple ways of adaptation to the treatment. At the same time, mutual interaction of plasma cells with the surrounding tumor microenvironment drives multiple metabolic alterations in the bone marrow. This provides a tumor-promoting environment, but at the same time may offer novel therapeutic options for the treatment of relapsed/refractory myeloma patients.

show abstract

“…The method cannot discriminate for drug efficacy/potency over different interacting subpopulations in a microenvironment. Hence, this can lead to misinterpretation of the biological effect of drugs, especially in relapsed/refractory patients where drug-resistant cancer population drives the disease Information Classification: General progression with the help of microenvironment (44). The luminesce or fluorescence-based bulk assays may be inappropriate for drug screening focused on identifying new drugs targeted for tumormicroenvironment interactions, as it cannot quantify the effect of drugs on cell-cell interaction level (Figure 2).…”

Section: Experimental Techniques For Htsmentioning

confidence: 99%

High-throughput screening for drug discovery targeting the cancer cell-microenvironment interactions in hematological cancers

Giri

Ianevski

2021

Expert Opinion on Drug Discovery

View full text Add to dashboard Cite

Introduction:The interactions between leukemic blasts and cells within the bone marrow environment affect oncogenesis, cancer stem cell survival, as well as drug resistance in hematological cancers. The importance of this interaction is increasingly being recognized as a potentially important target for future drug discoveries and developments. Recent innovations in the high throughput drug screening related technologies, novel ex-vivo disease-models, and freely available machine-learning algorithms are advancing the drug discovery process by targeting earlier undruggable proteins, complex pathways, as well as physical interactions (e.g., leukemic cell-bone microenvironment interaction). Area covered:In this review, the authors discuss the recent methodological advancements and existing challenges to target specialized hematopoietic niches within the bone marrow during

show abstract

The role of bone marrow stromal cells in blood diseases and clinical significance as a crucial part of the hematopoietic microenvironment

Cited by 3 publications

References 0 publications

Shaping the Treatment Paradigm Based on the Current Understanding of the Pathobiology of Multiple Myeloma: An Overview

Shaping the Treatment Paradigm Based on the Current Understanding of the Pathobiology of Multiple Myeloma: An Overview

Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors

High-throughput screening for drug discovery targeting the cancer cell-microenvironment interactions in hematological cancers

Contact Info

Product

Resources

About